The UK Government has announced that some adults and adolescents hospitalised with Covid-19 on the National Health Service (NHS) will have access to Gilead Sciences’ remdesivir.
The announcement comes after the country’s Medicines and Healthcare products Regulatory Agency (MHRA) provided positive scientific opinion under the Early Access to Medicines Scheme (EAMS).
Currently, remdesivir will only be given to patients who meet certain clinical criteria to help their recovery in hospital. Due to limited supplies, the drug will be prioritised for patients who have the greatest likelihood of experiencing the most benefit.